Metformin Effects According to SLC16A11 Carrier Status (NCT07760883)
Effect of Metformin in Individuals With Type 2 Diabetes According to SLC16A11 Risk Variant Carrier Status
🩺 Plain-English Summary (8th-Grade Level)
This prospective observational study will evaluate whether the SLC16A11 risk variant influences the response to metformin in adults with type 2 diabetes. Participants will be classified as carriers or noncarriers and followed for 6 months while receiving extended-release metformin titrated to the maximum tolerated dose, between 1,500 and 2,250 mg/day. The primary outcome is the change in glycated hemoglobin, with additional assessment of seven-point capillary glucose profiles, liver enzymes, visceral fat, lipid profile, and lactate concentrations. The study plans to include 154 participants to compare treatment response between both genetic groups and explore the potential value of a more personalized therapeutic approach.
Who can join: Review the eligibility criteria below.
Location: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán — Mexico City, Mexico City
Age range: 18 Years to 65 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán — Mexico City, Mexico City
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diabetes Type 2
- Deploying Digital Prosthetic Interface Technology and Exercise in Dysvascular Amputees — Boston, Massachusetts
- Evaluation of Pharmacist Intervention for Individuals With Uncontrolled Type 2 Diabetes — Portage la Prairie, Manitoba
- Enhancing Diabetes Care by Treating Insomnia — Zachary, Louisiana
- Canagliflozin Targeting Vascular Inflammation — Ottawa, Ontario
- Effect of the Thrive AI Health App on Lifestyle Behaviors and Quality of Life — New Haven, Connecticut
Explore by condition: All Diabetes Type 2 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.